Latest News | Lupin Launches Generic Medication in US Market

New Delhi, Mar 1 (PTI) Drug maker Lupin on Tuesday said it has launched Sevelamer Hydrochloride tablets (800 mg), used to treat hyperphosphatemia in patients with chronic kidney disease, in the US market.

The company has launched the product after having received approval from the US Food and Drug Administration (USFDA).

Also Read | Tesla Offers Free EV Charging in Several Countries Around Ukraine Following Russian Invasion: Report.

The medication will be manufactured at the company's manufacturing facility in Nagpur, Lupin said in a statement.

Hyperphosphatemia refers to abnormally high serum phosphate levels.

Also Read | Redmi Note 11E Pro With 5,000mAh Battery Launched; Prices, Features & Specifications.

The company's product is a generic equivalent of Genzyme Corporation's Renagel tablets.

As per IQVIA MAT December 2021 data, Sevelamer Hydrochloride tablets (800 mg) had an estimated annual sales of USD 75 million in the US.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)